Latest Pluripotency Stories
A team of researchers has now compared the ability of cells derived from different types of human stem cell to reverse disease in a rat model of Parkinson's disease and identified a stem cell population that they believe could be clinically relevant.
A team of researchers â€” led by Sang-Hun Lee, at Hanyang University, Republic of Korea, and Kwang-Soo Kim, at Harvard Medical School, Belmont, â€” has now compared the ability of cells derived from different types of human stem cell to reverse disease in a rat model of Parkinson disease and identified a stem cell population that they believe could be clinically relevant.
Ever since animals, such as lizards and starfish, were observed regenerating missing body parts, people have wondered where the new tissues come from.
A single adult cell from one of the most impressive masters of regeneration in the animal kingdom â€“ the planarian â€“ is all it takes to build a completely functional new worm, researchers have learned.
Stem cells are considered by many to be promising candidate sources of cells for therapies to regenerate and repair diseased tissues.
A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.
MADISON, Wis., April 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI), the world's largest producer of tissue cells derived from human induced pluripotent stem cell (iPSC) lines, today announced it has strengthened its intellectual property (IP) portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte, Inc., a stem cell company focused on diabetes therapy.
A paper published by Cell Press in the April 8th issue of the journal Cell Stem Cell reveals a new and more efficient method for reprogramming adult mouse and human cells into an embryonic stem cell-like state and could lead to better strategies for developing stem cells for therapeutic use.
Move over, newts and salamanders.
PARIS, April 5, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, has announced today that its subsidiary Ectycell has signed an agreement with the Caisse des Depots (a French financial institution) for a planned capital investment of euro 12M, in two steps, reserved in equal parts to Cellectis and Caisse des Depots. This agreement should start no later than January 31, 2012, and is subject to the achievement of certain technical conditions. Following this...